# A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

> **NCT00420849** · PHASE3 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 587 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00420849
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-10
- **Final completion:** 2009-11
- **Target enrollment:** 587 (ACTUAL)
- **Last updated:** 2012-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420849, "A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00420849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*